OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $18.50.

OPRX has been the topic of a number of research analyst reports. UBS Group set a $23.00 target price on OptimizeRx in a research report on Friday, October 10th. JMP Securities raised their price target on OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday. Stephens lowered their target price on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Monday, November 17th. Finally, Citizens Jmp lifted their target price on shares of OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th.

OptimizeRx Stock Performance

Shares of OptimizeRx stock opened at $12.74 on Friday. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. OptimizeRx has a 52 week low of $3.99 and a 52 week high of $22.25. The firm’s 50 day moving average is $16.30 and its two-hundred day moving average is $15.96. The firm has a market capitalization of $237.47 million, a P/E ratio of 33.22 and a beta of 1.10.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Thursday, November 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.17. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. The business had revenue of $26.07 million during the quarter, compared to analysts’ expectations of $23.83 million. Research analysts forecast that OptimizeRx will post -0.33 EPS for the current fiscal year.

Insider Buying and Selling

In other OptimizeRx news, CEO Stephen L. Silvestro sold 1,620 shares of OptimizeRx stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the transaction, the chief executive officer directly owned 188,916 shares in the company, valued at approximately $3,542,175. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors have recently added to or reduced their stakes in OPRX. Charles Schwab Investment Management Inc. lifted its position in OptimizeRx by 30.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,228 shares of the company’s stock worth $470,000 after acquiring an additional 12,676 shares during the period. Invesco Ltd. purchased a new stake in shares of OptimizeRx during the first quarter worth approximately $2,542,000. Nuveen LLC purchased a new stake in shares of OptimizeRx during the first quarter worth approximately $455,000. Russell Investments Group Ltd. lifted its holdings in shares of OptimizeRx by 25,355.6% during the first quarter. Russell Investments Group Ltd. now owns 45,820 shares of the company’s stock worth $397,000 after purchasing an additional 45,640 shares during the period. Finally, American Century Companies Inc. grew its position in OptimizeRx by 9.6% in the 1st quarter. American Century Companies Inc. now owns 15,783 shares of the company’s stock valued at $137,000 after buying an additional 1,387 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.